Lupin receives USFDA nod for Potassium Chloride ER capsules
Source: IRIS | 17 Aug, 2016, 04.10PM
|
|
|
|
Rating: NAN / 5 stars. |
Comments | Post Comment |
|
Pharma Major Lupin announced today that its US subsidiary, Gavis Pharmaceuticals LLC., U.S.A. (collectively Lupin) has received final approval for its Potassium Chloride Extended Release Capsules USP, 8 mEq (600 mg) and 10 mEq (750 mg) from the United States Food and Drug Administration (FDA) to market a generic equivalent of Actavis Labs FL, Inc's Potassium Chloride Extended Release Capsules USP, 8 mEq and 10 mEq.Lupin's Potassium Chloride Extended-Release Capsules USP, 8 mEq (600 mg) and 10 mEq (750 mg) are the AB rated generic equivalent of Actavis Labs FL, Inc's Potassium Chloride Extended-Release Capsules USP, 8 mEq and 10 mEq.
|
|
|
|
|
|
|
|
|
|
|
|